MA28702B1 - Composes et procedes pour l'inhibition de l'interaction de proteines bcl avec des partenaires de liaison - Google Patents

Composes et procedes pour l'inhibition de l'interaction de proteines bcl avec des partenaires de liaison

Info

Publication number
MA28702B1
MA28702B1 MA29588A MA29588A MA28702B1 MA 28702 B1 MA28702 B1 MA 28702B1 MA 29588 A MA29588 A MA 29588A MA 29588 A MA29588 A MA 29588A MA 28702 B1 MA28702 B1 MA 28702B1
Authority
MA
Morocco
Prior art keywords
compounds
methods
protein interaction
bcl protein
inhibiting bcl
Prior art date
Application number
MA29588A
Other languages
English (en)
Inventor
Alfredo C Castro
Wei Deng
Kristopher M Depew
Michael A Foley
Christian C Fritz
Evangelinos Asimina T Georges
Michael J Grogan
Nafeeza Hafeez
Edward B Holson
Brian T Hopkins
Nii O Koney
Tao Liu
David A Mann
Lisa A Marcaurelle
Daniel A Snyder
Dennis J Underwood
Andrew A Wylie
Lin-Chen Yu
Linping Zhang
Original Assignee
Infinity Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Infinity Discovery Inc filed Critical Infinity Discovery Inc
Publication of MA28702B1 publication Critical patent/MA28702B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
MA29588A 2004-06-17 2006-12-29 Composes et procedes pour l'inhibition de l'interaction de proteines bcl avec des partenaires de liaison MA28702B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58061604P 2004-06-17 2004-06-17
US65930105P 2005-03-07 2005-03-07

Publications (1)

Publication Number Publication Date
MA28702B1 true MA28702B1 (fr) 2007-06-01

Family

ID=35335774

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29588A MA28702B1 (fr) 2004-06-17 2006-12-29 Composes et procedes pour l'inhibition de l'interaction de proteines bcl avec des partenaires de liaison

Country Status (22)

Country Link
US (1) US7851637B2 (fr)
EP (1) EP1768966B1 (fr)
JP (1) JP5064213B2 (fr)
KR (1) KR101195351B1 (fr)
CN (1) CN101006065B (fr)
AT (1) ATE548359T1 (fr)
AU (1) AU2005265131B2 (fr)
BR (1) BRPI0511070A (fr)
CA (1) CA2570780C (fr)
EC (1) ECSP067099A (fr)
ES (1) ES2382383T3 (fr)
HK (1) HK1105963A1 (fr)
IL (1) IL179904A (fr)
MA (1) MA28702B1 (fr)
MX (1) MXPA06014754A (fr)
NO (1) NO20070324L (fr)
NZ (1) NZ552183A (fr)
PL (1) PL1768966T3 (fr)
PT (1) PT1768966E (fr)
RU (1) RU2416606C2 (fr)
WO (1) WO2006009869A1 (fr)
ZA (1) ZA200610405B (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1768966T3 (pl) 2004-06-17 2012-08-31 Infinity Discovery Inc Związki i sposoby hamowania oddziaływania białek BCL z partnerami wiążącymi
US7842815B2 (en) 2004-06-17 2010-11-30 Infinity Pharmaceuticals, Inc. Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
US8624027B2 (en) * 2005-05-12 2014-01-07 Abbvie Inc. Combination therapy for treating cancer and diagnostic assays for use therein
TWI403320B (zh) 2005-12-16 2013-08-01 Infinity Discovery Inc 用於抑制ｂｃｌ蛋白和結合夥伴間之交互作用的化合物及方法
TWI389895B (zh) 2006-08-21 2013-03-21 Infinity Discovery Inc 抑制ｂｃｌ蛋白質與結合夥伴間之交互作用的化合物及方法
EP1897956A1 (fr) 2006-09-06 2008-03-12 Lonza AG Procédé de préparation d'amines optiquement actives par résolution optique en utilisant d'une oméga-transaminase bactérienne
CN104474529A (zh) * 2008-02-08 2015-04-01 爱勒让治疗公司 治疗性的拟肽大环化合物
US20110086834A1 (en) * 2008-06-26 2011-04-14 Amgen Inc. Alkynyl alcohols as kinase inhibitors
US8980254B2 (en) 2008-08-21 2015-03-17 Alvine Pharmaceuticals, Inc. Formulation for oral administration of proteins
US20100160322A1 (en) 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
UA108193C2 (uk) * 2008-12-04 2015-04-10 Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
US8557983B2 (en) 2008-12-04 2013-10-15 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
HUE029289T2 (en) * 2008-12-05 2017-02-28 Abbvie Inc Sulfonamide derivatives as Bcl-2 selective apoptosis inducers for the treatment of cancer and immune diseases
US8586754B2 (en) 2008-12-05 2013-11-19 Abbvie Inc. BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US8563735B2 (en) 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US8546399B2 (en) * 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
PE20120345A1 (es) * 2009-05-26 2012-05-17 Abbvie Bahamas Ltd Derivados de 2-(1h-pirrolo[2,3-b]piridin-5-iloxi)-n-fenilsulfonilbenzamida como inhibidores de proteinas anti-apoptoticas
US8314250B2 (en) * 2009-11-24 2012-11-20 Hoffmann-La Roche Inc. Sultam derivatives
MX2016009753A (es) 2014-01-28 2017-07-07 Buck Inst For Res On Aging Metodos y composiciones para exterminar celulas senescentes y para tratar enfermedades y trastornos asociados con la senectud.
WO2015160975A2 (fr) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Polythérapies
US10709692B2 (en) * 2015-12-04 2020-07-14 Denali Therapeutics Inc. Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (RIPK1)
CA3018932C (fr) 2016-03-28 2021-10-26 Presage Biosciences, Inc. Combinaisons pharmaceutiques pour le traitement du cancer
WO2021233948A1 (fr) 2020-05-19 2021-11-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédé de traitement d'une infection pulmonaire par un pathogène
WO2022008464A1 (fr) 2020-07-06 2022-01-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinaison d'antibiotiques anti néoplasiques et d'inhibiteurs de bcl-2 pour le traitement de la leucémie myéloïde aiguë (lma) entraînée par npm-1

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH445129A (fr) 1964-04-29 1967-10-15 Nestle Sa Procédé pour la préparation de composés d'inclusion à poids moléculaire élevé
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
US3426011A (en) 1967-02-13 1969-02-04 Corn Products Co Cyclodextrins with anionic properties
US3453257A (en) 1967-02-13 1969-07-01 Corn Products Co Cyclodextrin with cationic properties
US3453259A (en) 1967-03-22 1969-07-01 Corn Products Co Cyclodextrin polyol ethers and their oxidation products
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
JPS55133364A (en) * 1979-04-03 1980-10-17 Mitsubishi Petrochem Co Ltd Preparation of isoxazolidine derivative
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
DE3643012A1 (de) 1986-12-17 1988-06-30 Hoechst Ag 2,3-disubstituierte isoxazolidine, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung
DE3829594A1 (de) * 1988-09-01 1990-03-15 Bayer Ag Neue renininhibitoren, verfahren zur herstellung und ihre verwendung in arzneimitteln
DE3926822A1 (de) * 1989-08-14 1991-02-21 Hoechst Ag Peptide mit bradykinin-antagonistischer wirkung
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
KR100188801B1 (ko) 1990-05-18 1999-06-01 엥겔하르트 라피체 이속사졸-4카복스아미드 및 하이드록시알킬리덴 시아노아세트아미드 및 이들 화합물을 함유하는 약제학적 조성물
US5294617A (en) 1993-04-23 1994-03-15 American Cyanamid Company Angiotensin II receptor blocking 2,3,6 substituted quinazolinones
BR9408137A (pt) 1993-11-24 1997-08-12 Du Pont Merck Pharma Composto éster de prodroga método de tratamento composição farmacêutica e método de inibição
EP0730587B1 (fr) * 1993-11-26 1999-12-08 Pfizer Inc. 3-phenyl-2-isoxazolines utiles comme agents anti-inflammatoires
ES2118557T3 (es) 1994-03-09 1998-09-16 Pfizer Compuestos de isoxazolina como inhibidores de la liberacion de tnf.
IL115849A0 (en) 1994-11-03 1996-01-31 Merz & Co Gmbh & Co Tangential filtration preparation of liposomal drugs and liposome product thereof
US5514505A (en) 1995-05-15 1996-05-07 Xerox Corporation Method for obtaining improved image contrast in migration imaging members
DE19539638A1 (de) 1995-10-25 1997-04-30 Hoechst Ag Die Verwendung von Isoxazol- und Crotonsäureamidderivaten zur Behandlung von Krebserkrankungen
US6221865B1 (en) * 1995-11-06 2001-04-24 University Of Pittsburgh Inhibitors of protein isoprenyl transferases
IT1283836B1 (it) 1996-08-28 1998-04-30 Viv Int Spa Procedimento per decorare profilati metallici,in materiale plastico e simili e relativa apparecchiatura
WO1998016830A2 (fr) 1996-10-16 1998-04-23 The President And Fellows Of Harvard College Systeme de criblage par gouttelettes
WO1998050031A1 (fr) * 1997-05-07 1998-11-12 University Of Pittsburgh Inhibiteurs de proteines isoprenyle transferases
WO2001016115A1 (fr) 1999-09-01 2001-03-08 Chemrx Advanced Technologies, Inc. Procede relatif a la synthese d'isoxazolidines
KR100399361B1 (ko) * 1999-11-04 2003-09-26 주식회사 엘지생명과학 캐스파제 억제제 함유 치료제 조성물
DE60237115D1 (de) 2001-05-30 2010-09-02 Univ Georgetown Synergistische Kombination von (-) -Gossypol mit Docetaxel oder Paclitaxel zur Behandlung von Krebs.
US20030119894A1 (en) 2001-07-20 2003-06-26 Gemin X Biotechnologies Inc. Methods for treatment of cancer or neoplastic disease and for inhibiting growth of cancer cells and neoplastic cells
FR2840807B1 (fr) 2002-06-12 2005-03-11 Composition cosmetique de soin et/ou de maquillage, structuree par des polymeres silicones et des organogelateurs, sous forme rigide
PL1768966T3 (pl) 2004-06-17 2012-08-31 Infinity Discovery Inc Związki i sposoby hamowania oddziaływania białek BCL z partnerami wiążącymi

Also Published As

Publication number Publication date
CN101006065A (zh) 2007-07-25
JP5064213B2 (ja) 2012-10-31
ATE548359T1 (de) 2012-03-15
RU2007101276A (ru) 2008-08-10
EP1768966B1 (fr) 2012-03-07
NZ552183A (en) 2009-10-30
KR20070046068A (ko) 2007-05-02
CA2570780C (fr) 2013-12-03
CN101006065B (zh) 2012-07-11
RU2416606C2 (ru) 2011-04-20
PL1768966T3 (pl) 2012-08-31
IL179904A (en) 2011-11-30
KR101195351B1 (ko) 2012-10-29
CA2570780A1 (fr) 2006-01-26
PT1768966E (pt) 2012-05-23
JP2008503489A (ja) 2008-02-07
BRPI0511070A (pt) 2007-11-27
EP1768966A1 (fr) 2007-04-04
AU2005265131B2 (en) 2012-02-23
WO2006009869A1 (fr) 2006-01-26
AU2005265131A1 (en) 2006-01-26
IL179904A0 (en) 2007-05-15
NO20070324L (no) 2007-03-19
MXPA06014754A (es) 2007-06-22
US7851637B2 (en) 2010-12-14
US20060025460A1 (en) 2006-02-02
HK1105963A1 (en) 2008-02-29
ECSP067099A (es) 2007-04-26
ES2382383T3 (es) 2012-06-07
ZA200610405B (en) 2008-03-26

Similar Documents

Publication Publication Date Title
MA28702B1 (fr) Composes et procedes pour l'inhibition de l'interaction de proteines bcl avec des partenaires de liaison
MY156754A (en) Compounds and methods for inhibiting the interaction of bcl proteins with binding partners
JO2917B1 (en) Compounds and methods to inhibit the interaction between BCL and binding partners
MA30144B1 (fr) Composes et procedes d'inhibition de l'interaction des proteines bcl avec des partenaires de liaison
ZA200501128B (en) Biphasic composition induced by polydextrose
SG171682A1 (en) Iap bir domain binding compounds
WO2002089738A3 (fr) Composes proteomimetiques et procedes correspondants
GB0510143D0 (en) Novel compounds A1
SG10201407388XA (en) Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
ATE554087T1 (de) Neue kinaseinhibitoren
TW200602029A (en) Inhibitors of IAP
MA31451B1 (fr) Antagonistes des recepteurs de l'orexine de pyridyl piperidine.
BG66084B1 (bg) Циклопентаноиндоли, състави,съдържащи такива съединения и използването им
MX2009003981A (es) Agentes moduladores del receptor de calcio.
TW200724140A (en) Hydantoin compounds
WO2007022947A3 (fr) Composes 5-cycle-heteroaromates et leur utilisation en tant que partenaires de liaison des recepteurs 5-ht5
ATE423100T1 (de) Neue chinolinverbindungen, die dazu in der lage sind, sich an den cb2-rezeptor zu binden
EA200600860A1 (ru) Производные n-тиазол-2-илбензамида
MX2009012316A (es) Metodos de tratamiento de trastornos cognitivos mediante la inhibicion de gpr12.
DE602005014632D1 (de) Pyrrol- bzw. imidazolamide zur behandlung von obesitas
EE200300092A (et) EDb-fibronektiinidomeeni retseptor
TNSN06418A1 (en) Compounds and methods for inhibiting the interaction of bcl proteins with binding partners
MY155908A (en) Compounds and methods for inhibiting the interaction of bcl proteins with binding partners
UA115859C2 (uk) Розчинний поліпептид, який зв'язує активін а, та композиція, що його містить